Skip to main content

Novel Rx

No Great Options for Treating VEXAS

MedPage Today

For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.

Among 110 patients in the

Read Article
Save the date! We’ll be covering #EULAR24! https://t.co/HGjP2SFyOp
Dr. John Cush @RheumNow( View Tweet )
In animal models, IL-22 may have protective effects against pulm fibrosis. Study of 66 new #RA pts (1/2 w/ ILD) & 14 controls. Serum IL-22 was signif lower in RA-ILD; and was inversely correlated with the severity of RA-ILD https://t.co/Rmr5N2JznH https://t.co/OZ1ZrgGXC3
Dr. John Cush @RheumNow( View Tweet )

Small-molecule Drugs to Treat Systemic Lupus Erythematosus

A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs. 

Read Article
The EMAs CHMP has recommended for approval Two biosimilars, Tofidence (tocilizumab) and Wezenla (ustekinumab) https://t.co/mREclYdeCk https://t.co/zQX00Ys8oH
Dr. John Cush @RheumNow( View Tweet )
French insurance claims study of 12071 #PsA pts on biologics (2015-2021) found total of 367 serious infections (3%; IR 1.7/100PY). SIR risk significantly lower for new users of etanercept (wHR 0.72) & ustekinumab (wHR 0.57) (vs ADA new users https://t.co/CutqoxA05e https://t.co/OUCUbrKnFF
Dr. John Cush @RheumNow( View Tweet )

Pharmacologic Efficacy in Still's Disease

A systematic review of the effectiveness and safety of pharmacological treatments for adult-onset Still’s disease (AOSD) supports the use of either IL-1 or IL-6 inhibitors.

A metanalysis was performed using databases, trial

Read Article
FDA has approved the adalimumab biosimilar Cyltezo (adalimumab-adbm) for the 2nd time, now as a high-concentration, citrate-free formulation for injection (from Boehringer Ingelheim) https://t.co/micTFhjgqm

Dr. John Cush @RheumNow( View Tweet )

🏆Dr. Georg Schett's pioneering work in CAR-T for #autoimmune disease has landed him among the TIME100 Most Influential People in Health “Not only are the patients in drug-free remission, but I believe many are cured of their autoimmune disease," he said https://t.co/Rj7FpkluNg

Healio Rheumatology @HealioRheum( View Tweet )

CAR T-Cell Therapy in Autoimmune Disease | New England Journal of Medicine https://t.co/VKlNGVDfyw. - persistence of CAR-T cells needs exploration

Peter Nash @drpnash( View Tweet )

With the FDA's approval of its 50th biosimilar - they have published "A Milestone in Facilitating the Development of Safe and Effective Biosimilars". Since biosimialrs were approved in 2015, they saved the health care system $23.6 billion. https://t.co/7GPJ5XLGnr https://t.co/6Qw7DttmjT
Dr. John Cush @RheumNow( View Tweet )

Rheum Chapter Notes (4.26.2024)

Dr. Jack Cush reviews this past week’s news and journal articles from RheumNow.com.

Read Article
50 active RA pts RCT Rx w. either low dose IL-2(n=26), IL-2+TCZ (9) or control (15). All improved clinically by DAS28-ESR, but IL-2 Rx pts had signif proliferation of Tregs, w. decr inTh1, Th2, & Th17 cells. TREG #s correlated w/ ESR drop (r=0.54) https://t.co/1tF63FuXzx https://t.co/M5TWsa6zI4
Dr. John Cush @RheumNow( View Tweet )
Dawn of CAR-T cell therapy in autoimmune diseases - A review article from the Chinese Medical Journal https://t.co/Qbort9Rsmh https://t.co/wWwTXkZiXj
Dr. John Cush @RheumNow( View Tweet )
AbbVie announced preliminary positive results from phase 3 SELECT-GCA study showing remission in 46% of #GCA pts Rx w/ upadacitinib for 52wks (vs 29% PBO); RCT included a 26-wk steroid taper regimen https://t.co/DIstJ4hazo https://t.co/VXc7rj0REJ
Dr. John Cush @RheumNow( View Tweet )

Canary in a Coal Mine (4.19.2024)

Dr. Jack Cush reviews regulatory reports, news and novel journal articles - this week focusing on Sjogren's, ILD, Gout and Uveitis.

Read Article
FDA has approved a ustekinumab biosimilar (ustekinumab-aekn; AKA Selardsi), made by Teva & Alvotech, for the treatment of moderate to severe plaque psoriasis (PsO) and active psoriatic arthritis (PsA) in both adults and pediatric pts.https://t.co/ZXvFjjH7Qt https://t.co/7FJKxSVAgL
Dr. John Cush @RheumNow( View Tweet )

Lupus Accelerating Breakthroughs Consortium Partners with FDA

EurekAlert!

The Lupus Research Alliance (LRA), founder and administrator of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), announced today at the Consortium’s first anniversary meeting an expanded partnership with the U.S. Food and Drug Administration (FDA) with the inclusion of the Center

Read Article
PNAS: Autoimmunity against MDA5 induces fibrotic ILD in mice. In this murine model of dermatomyositis, treatment with either anti-CD4 or anti-IL-6 receptor antibody ameliorated the MDA5-induced fibrotic ILD. https://t.co/CahyGfTn4g https://t.co/lfpdgEvGmx
Dr. John Cush @RheumNow( View Tweet )
IL-1 recept accessory protein (IL1RAP) shown to block mediators (IL-1, IL33, IL36) that may drive systemic sclerosis. In vitro, IL1RAP inhibited fibroblasts and endothelial cells; in mouse models of SSc anti-IL1RAP decr dermal & pulmonary fibrosis. https://t.co/6YE02P4rjR https://t.co/mzw7t88Jzl
Dr. John Cush @RheumNow( View Tweet )
This study examined the risk of neuroinflammatory disease after initiation of b/tsDMARDs Overall risk of neuroinflammatory events among new users of TNF inhibitors did not differ substantially as compared to new users of other b/tsDMARDs In AC&R https://t.co/8rGgZmpq9c https://t.co/5gxuWBctBL
ACR_Journals @ACR_Journals( View Tweet )

ICYMI: Sex Disparities in PsA/SpA

Dr. Eder delivered an illuminating talk at RheumNow Live 2024 on sex differences in psoriatic arthritis; the disease may manifest differently in men and women, and therapeutic responses may differ between the sexes.

Read Article

JAMA: SLE Review

Drs. Caroline Siegel and Lisa Sammaritano (from HSS in NYC) have published an impressive overview of systemic lupus erythematosus (SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide.

Read Article
FDA Curriculum and Toolkit on Biosimilars for educators; Fact sheets on: - Biologicals, Biosimilars & InterchangeableProducts - Generics & Biosimilars - Manufacturing & Variation - Biosimilar Regulatory Approval Pathway https://t.co/bHYFPb8VxU https://t.co/bA8I567H8U
Dr. John Cush @RheumNow( View Tweet )
Research on SGLT2 inhibitors in #gout is needed. They have been shown to reduce uric acid & gout flares, and may be uricosuric or be antiinflammatory. Also decreased incident gout (by half) among at-risk patients with type 2 diabetes (HR 0.54) https://t.co/CGG9aFsgoD https://t.co/5O2f3MFL8C
Dr. John Cush @RheumNow( View Tweet )